Herceptin(Truastuzumab)--anti-HER2/neu antibody
Day 3 - July 30,
2000
Literature review
Session 1: Anti-Her2 Therapy
Breast cancer
SD H: Standard Herceptin Dose 4mg/kg Loading dose; 2mg/kg reminding dose
Stage Pts pool Dose Response Reference Review Monoclonal antibody approved for metastatic breast cancer. - - Oncology (Huntingt). 1998 Dec;12(12):1727. Review Herceptin (trastuzamab) in advanced breast cancer. - - Cancer Treat Rev. 2000 Aug;26(4):287-290. Review Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin). - - Semin Oncol. 2000 Apr;27(2 Suppl 3):19-23. Review. Adjuvant Herceptin in the adjuvant setting: phase III trials begin. - - J Natl Cancer Inst. 2000 May 3;92(9):683-4. Model Antitumor activity of Herceptin in combination with STEALTH liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model. - - J Inorg Biochem. 1999 Oct;77(1-2):117-20. Dose finding Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. - - Br J Cancer. 1999 Dec;81(8):1419-25. - Weekly paclitaxel plus Herceptin in metastatic breast cancer patients who relapse after stem-cell transplant. - - Ann Oncol. 1999 Oct;10(10):1259-60. Phase II Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. - - Semin Oncol. 1999 Aug;26(4 Suppl 12):78-83. Dose finding MBC 1st/No Hormone 25% ACSO 2000 abstract 275 Quality of Life MBC 1st SD H - ACSO 2000 abstract 1710 - MBC 1st SD H+ weekly Taxol(90mg/m2) 59% ACSO 2000 abstract 319 - MBC SD H+1HrTaxol - ACSO 2000 abstract 559 Phase II MBC SD H+Docetaxel - ACSO 2000 abstract 512 - MBC SD H+Docetaxel ACSO 2000 abstract 586 Phase II MBC all stage SD H+weekly Navelbine(25mg/m2) ORR/71% 1St/77% 2nd/60% 3rd/83% ACSO 2000 abstract 392
Other Tumor
Stage Pts pool Dose Response Reference Cardiotoxicity associated with paclitaxel/trastuzumab combination therapy. - - J Clin Oncol. 1999 May;17(5):1647-8. Myocardium HER2-Expression in the Myocardium as a Cause for the Cardiotoxicity of Trastuzumab (Herceptin)? - - ASCO 2000 abstract 370 - Bleeding risk with trastuzumab (Herceptin) treatment. - - JAMA. 1999 Dec 22-29;282(24):2299-301.
Session 2: Her2
Session 3: Her2 in Cancer treatment
Tumor type Title Reference Breast cancer HER2 Overexpression Predicts Adjuvant Tamoxifen (TAM) Failure for Early Breast Cancer (EBC): Complete Data at 20 Yr of the Naples GUN Randomized Trial. ASCO 2000 abstract 289 Breast cancer A Metanalysis of the Interaction Between Her2 and the Response to Endocrine Therapy (ET) in Metastatic Breast Cancer (MBC). ASCO 2000 abstract 300 Breast cancer Biweekly Paclitaxel and Gemcitabine in Advanced Breast Cancer. Phase II Trial and Predictive Value of HER2 Extracellular Domain (ECD). ASCO 2000 abstract 373 Myocardium HER2-Expression in the Myocardium as a Cause for the Cardiotoxicity of Trastuzumab (Herceptin)? ASCO 2000 abstract 370 Breast cancer Overexpression of HER-2/neu (c-erb B-2) Oncogene is Positively Correlated with an Extensive Intraductal Carcinoma (EIC) in Early Stage Breast Cancer. ASCO 2000 abstract 374 Breast cancer Her-2 Gene Amplification Correlates with Higher Levels of Angiogenesis in Primary Breast Tumors. ASCO 2000 abstract 2559 Prostate Cancer HER2 Expression in Androgen-Independent Prostate Cancer. ASCO 2000 abstract 1365 Lung Tumor Evaluation of HER2/neu Expression in Lung Tumors by Immunohistochemistry and Fluorescence in Situ Hybridization (FISH). ASCO 2000 abstract 1900 NSCLC HER-2/neu Expression in Archival Non-Small Cell Lung Carcinomas (NSCLC) Using FDA-Approved Herceptest and Clinical Correlation. ASCO 2000 abstract 2012
Session 4: Testing Her2 Overexpression/Amplification